Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novavax

Novavax Rockets 28% On Upbeat Sales View, Cuts Workforce By A Quarter

Novavax an offered upbeat sales view Tuesday and announced a 25% reduction in its workforce to help cut costs — and NVAX stock rocketed.

Investors Business Daily

Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't?

Novavax has a solid platform but continues to face a $700 million litigation headwind, an analyst said Thursday as he downgraded NVAX stock.

Investors Business Daily

Sanofi: the new protein-based Covid vaccine to be used in the UK

The University of Edinburgh’s Neil Mabbott on the vaccine technology being used for Covid booster jabs from this month.

The Week

From analysis to the latest developments in health,
read the most diverse news in one place.

Everything we know about new Sanofi Covid vaccine now being used in UK

The vaccine being used in the Spring booster campaign works in a different way to previous jabs

Wales Online

Sanofi vaccine: what to know about this protein-based COVID booster being offered in the UK

In the UK a spring booster campaign has recently begun, offering an additional vaccine to people at highest risk from COVID. Between April and June 2023 people aged over 75, residents in care homes and children and adults aged five and up with weakened immune systems will be invited to…

The Conversation

Cancer and heart disease vaccines ‘ready by end of the decade’

Exclusive: Pharmaceutical firm says groundbreaking jabs could save millions of lives

The Guardian - UK

Novavax Stock Plummets On 'Substantial Uncertainty' For Its Future

Novavax says there's "substantial doubt" regarding its ability to continue, and NVAX stock crashed Wednesday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Experts unsure about who needs boosters

FDA expert committee needs more data to decide when to give out COVID boosters — and who needs them most

Salon

Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip

Novavax plans to update its Covid vaccine for new variants, and NVAX stock outperformed its vaccine stock rivals.

Investors Business Daily

FDA experts are still puzzled over who should get which COVID-19 shots and when

At a meeting to simplify the nation’s COVID-19 vaccination policy, the FDA’s panel of experts could agree on only one thing: Information is woefully lacking about how often different groups of Americans need to be vaccinated. That data gap has contributed to widespread skepticism, undervaccination, and ultimately unnecessary deaths from…

Tribune News Service

FDA advisers back the same COVID vaccine for initial shots, boosters

Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of targeting the same coronavirus strain for initial COVID-19 vaccine doses and boosters going forward, but some expressed skepticism about whether all Americans need to receive the shots annually.

Reuters

Vaccines are not making COVID strains like 'Kraken' stronger

Scientists say there is no evidence to suggest that vaccinations are making COVID "stronger" and that mutations are a normal part of virus evolution.

Fortune

RSV: experts explain why rates of this virus are surging this year

Respiratory syncytial virus (RSV) is a very common virus, typically causing infection in children during the colder months. In most cases, RSV causes a mild illness, with symptoms similar to that of a regular cold.

The Conversation

COVID-19 booster uptake remains low, despite growing evidence they’re as good as older shots

DENVER — More than two months into the campaign to get people to take updated COVID-19 boosters, only about 8% of people who are eligible have received the shot, though about 23% of those 65 and older have, according to Centers for Disease Control and Prevention estimates.

The Denver Post

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biotech Firestorm Takes Down Novavax Despite Quadrupled Sales

Novavax posted an unexpected third-quarter loss, and NVAX stock yo-yoed Wednesday despite better-than-expected sales.

Reuters

Novavax says Omicron shot shows strong immune response as second booster

Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.

The Independent UK

US clears Novavax COVID booster dose

The Food and Drug Administration has authorized a booster dose of the COVID-19 vaccine made by Novavax

Investors Business Daily

Why Novavax's Uphill Battle Continues Despite Winning U.S. Booster Authorization

Novavax won Food and Drug Administration for its Covid booster on Wednesday, but NVAX stock dipped slightly in response.

Get all your
news in one place.

100’s of premium titles.
One news app.

ABC News

What vaccine can you get, based on your age? These are the recommended COVID-19 vaccines for each age group

More than 14.2 million Australians over the age of 16 have now received three or more doses. So which are the best vaccines for each age group?

Benzinga

Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On?

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

Investors Business Daily

Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak

Novavax stock is trading at a two-year low amid slowly ramping use of its Covid vaccine, dubbed Nuvaxovid, in the U.S.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022

Upgrades

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Investors Business Daily

The Covid Gambit: Pfizer, Moderna Struggle To Get The Jump On Covid

Companies are working to develop updated Covid boosters. Will they be too late to make a difference for the vaccine stocks — and society?

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

344 stories

PFE

299 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.